List of Excipients in Branded Drug GOOD SENSE LOPERAMIDE HYDROCHLORIDE

Generic Drugs Containing GOOD SENSE LOPERAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
L Perrigo Company	loperamide hcl	0113-0645	ANHYDROUS CITRIC ACID
L Perrigo Company	loperamide hcl	0113-0645	CARBOXYMETHYLCELLULOSE SODIUM
L Perrigo Company	loperamide hcl	0113-0645	CELLULOSE, MICROCRYSTALLINE
L Perrigo Company	loperamide hcl	0113-0645	D&C YELLOW NO. 10
L Perrigo Company	loperamide hcl	0113-0645	FD&C BLUE NO. 1
L Perrigo Company	loperamide hcl	0113-0645	GLYCERIN

What are the Most Frequently-Used Excipients in GOOD SENSE LOPERAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	CARBOXYMETHYLCELLULOSE SODIUM
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	GLYCERIN

GoodSense Loperamide Hydrochloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

GoodSense loperamide hydrochloride is an OTC, immediate-release oral antidiarrheal positioned as a low-cost private-label alternative to branded Imodium products. Its commercial opportunity is driven less by active-ingredient exclusivity than by manufacturing cost, dosage-form differentiation, packaging, retail distribution, and consumer safety controls.

The core product strategy is a robust 2 mg immediate-release tablet or capsule using conventional pharmaceutical excipients. Meaningful differentiation can come from easier swallowing, rapid disintegration, unit-dose packaging, pediatric-use controls, and retailer-specific pack sizes. The principal regulatory constraint is loperamide misuse at high doses, which has been associated with serious cardiac events and death.[1]

What is GoodSense loperamide hydrochloride?

GoodSense loperamide hydrochloride is a store-brand OTC product containing loperamide hydrochloride, generally supplied as a 2 mg oral dosage unit. Loperamide reduces intestinal motility and increases fluid absorption by acting on peripheral opioid receptors in the gastrointestinal tract. At labeled doses, it is used for short-term control of nonspecific diarrhea.

The product competes with:

• Imodium A-D;
• Walgreens and CVS private-label loperamide;
• Walmart Equate anti-diarrheal products;
• generic pharmacy products;
• convenience-store and online OTC brands.

The GoodSense product should be assessed by NDC and dosage form because private-label products can have different contract manufacturers, inactive ingredients, packaging configurations, and labeling presentations under the same commercial brand.

Typical commercial specifications

Attribute	GoodSense loperamide profile
Active ingredient	Loperamide hydrochloride
Common strength	2 mg per tablet or capsule
Route	Oral
Product category	OTC antidiarrheal
Dosage forms	Immediate-release tablet, caplet, or capsule
Primary market	U.S. retail and e-commerce
Regulatory route	OTC monograph pathway or approved generic product, depending on product history
Main competitor	Imodium A-D
Core differentiation	Price, pack count, dosage form, retailer access, packaging

FDA’s OTC monograph framework identifies loperamide as an active ingredient for antidiarrheal products when used under specified conditions.[2]

What is the FDA regulatory status of GoodSense loperamide?

GoodSense loperamide is an OTC drug product, not a biologic, and it does not require biosimilar analysis. The relevant regulatory questions are whether the specific product complies with the applicable OTC monograph, whether its labeling follows FDA requirements, and whether its manufacturing site complies with current good manufacturing practice.

The regulatory pathway can vary by product history:

1. A monograph-compliant product may be marketed without an individual new drug application if all conditions are met.
2. A legacy product may have been associated with an abbreviated or full NDA before the OTC monograph framework.
3. A private-label product may be manufactured under contract for a distributor or retailer.
4. A reformulated product may require a new regulatory assessment if it departs from monograph conditions or introduces a novel dosage form.

FDA’s OTC Monograph Order Review process replaced the prior monograph final-rule structure under the CARES Act.[3] The applicable regulatory status must therefore be assessed against the current monograph order and the specific product labeling.

Is GoodSense listed in the Orange Book?

An OTC monograph product generally does not have the same Orange Book listing profile as an approved prescription generic. The Orange Book is principally relevant to approved prescription drugs and certain approved OTC products marketed under an NDA.

For GoodSense loperamide, the commercial risk analysis should focus on:

• FDA Drug Listing data;
• the product’s NDC;
• the applicable OTC monograph or approved application;
• labeler and contract-manufacturer records;
• current FDA warning letters, recalls, or compliance actions.

A lack of an Orange Book-listed patent does not mean the product is free of all intellectual-property risk. Packaging, device features, trademarks, manufacturing processes, and branded presentation can remain protected separately.

What patents protect GoodSense loperamide hydrochloride?

The loperamide active ingredient is an old, generic compound. Its basic composition-of-matter patent estate is not a meaningful barrier to entry for current OTC manufacturers. The commercial product is therefore exposed primarily to ordinary generic competition.

Relevant IP categories include:

IP category	Relevance to GoodSense
Composition of matter	Low relevance; loperamide is an established generic active ingredient
Basic 2 mg oral formulation	Usually weak unless a novel formulation is claimed
Immediate-release excipient system	Potentially protectable only if tied to unexpected performance or a specific formulation
Taste-masked formulation	Potential opportunity for chewable or liquid products
Abuse-deterrent formulation	Potential opportunity, but requires evidence and regulatory substantiation
Packaging and child resistance	Protectable through design, utility, or trade dress rights
Manufacturing process	Possible protection if a low-impurity or high-yield process is novel
Method of use	Limited opportunity for ordinary diarrhea treatment because the use is established
Trademark and trade dress	Relevant to GoodSense brand protection and retailer exclusivity

Are there active method-of-use patents for loperamide?

Ordinary treatment of acute nonspecific diarrhea is unlikely to provide a strong current patent barrier because the use is long established. New method-of-use claims could arise around specific patient populations, combination therapy, bowel-motility disorders, or controlled dosing, but those claims would not ordinarily block a standard OTC loperamide product.

A method-of-use patent also would not automatically prevent sale of a product for an unpatented, monograph-compliant indication unless the marketing or labeling induced the patented use.

What excipients are used in loperamide tablets and capsules?

Loperamide oral solid products generally use conventional excipients selected for immediate release, tablet strength, mechanical integrity, and low manufacturing cost. The exact GoodSense composition depends on the NDC and contract manufacturer.

Common excipient classes include:

Excipient class	Typical function	Strategic considerations
Microcrystalline cellulose	Diluent and compression aid	Supports direct compression and tablet hardness
Lactose, mannitol, or dibasic calcium phosphate	Filler	Affects density, mouthfeel, cost, and tolerability
Croscarmellose sodium or crospovidone	Superdisintegrant	Supports rapid tablet breakup
Pregelatinized starch	Binder and disintegrant	Useful in robust, low-cost tablet manufacture
Povidone	Binder	Can improve granule strength
Colloidal silicon dioxide	Glidant	Controls powder flow and content uniformity
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Talc	Processing aid or anti-adherent	Requires control of grade and contamination risk
Film-coating polymers	Protection, appearance, swallowability	Can improve handling and brand differentiation
Flavor and sweetener systems	Taste masking	Most relevant to chewable or liquid products

The formulation target should be rapid disintegration without excessive friability. Loperamide tablets contain a small quantity of active ingredient relative to the total unit weight, so blend uniformity and segregation control are important manufacturing risks.

How should an excipient strategy be designed for GoodSense loperamide?

The best baseline formulation is a low-cost, direct-compression or simple wet-granulation system with a strong disintegration profile. The objective is not maximum excipient complexity. It is consistent dose delivery, short manufacturing cycle time, stability, and reliable dissolution.

1. Build around a conventional immediate-release platform

A practical tablet platform would use:

• a compressible filler;
• one primary superdisintegrant;
• a low-level glidant;
• magnesium stearate or another approved lubricant;
• optional film coating.

Using two disintegrants can improve robustness, but it also increases formulation complexity and cost. The formulation should be tested across normal variations in compression force, lubricant mixing time, granulation moisture, and tablet hardness.

2. Control low-dose blend uniformity

The 2 mg strength creates a content-uniformity challenge. Particle-size mismatch between loperamide hydrochloride and the filler can cause segregation during blending, transfer, or hopper discharge.

Risk-reduction measures include:

• geometric dilution;
• controlled particle-size distribution;
• ordered mixing;
• low-shear transfer;
• validated blend sampling;
• compression-feed-frame control;
• avoidance of excessive vibration during packaging.

A granulation process may improve uniformity but can raise cost and introduce a drying step. Direct compression is commercially attractive if content uniformity and flow are demonstrated.

3. Use coating to improve consumer handling

A thin film coating can improve:

• swallowability;
• tablet appearance;
• dust control;
• moisture protection;
• differentiation from uncoated generic tablets.

The coating should not materially delay dissolution. A colored coating also increases product recognition but may introduce dye sensitivities, supplier qualification requirements, and retailer-specific color constraints.

4. Avoid unnecessary excipient liabilities

The product should be screened for:

• lactose intolerance concerns;
• sugar content;
• gluten-related consumer claims;
• artificial color;
• gelatin source;
• animal-derived ingredients;
• sorbitol-related gastrointestinal effects;
• allergen declaration requirements;
• nitrosamine and elemental-impurity risks from raw materials.

A fully lactose-free, sugar-free, and gelatin-free tablet can broaden consumer acceptance, although each claim must be supported by the formulation and labeling record.

What formulations are protected or commercially differentiated?

The standard 2 mg immediate-release tablet has limited patent differentiation. More defensible commercial opportunities exist in dosage forms that solve a specific consumer or safety problem.

Chewable tablets

Chewables could target consumers who have difficulty swallowing capsules or caplets. The main formulation issues are bitterness, aftertaste, dose uniformity, tablet hardness, and moisture sensitivity.

Potential excipient tools include:

• mannitol for cooling mouthfeel;
• sucralose or acesulfame potassium for sweetness;
• flavor systems;
• polymeric taste-masking coatings;
• ion-exchange resins;
• saliva-triggered disintegration systems.

A taste-masked chewable formulation could create a stronger product distinction than a conventional caplet. It would also require more extensive sensory and stability work.

Orally disintegrating tablets

An orally disintegrating loperamide product could address portability and swallowing barriers. The product would need rapid in-mouth dispersion without unacceptable bitterness.

Potential challenges include:

• low tablet strength;
• friability;
• moisture uptake;
• packaging cost;
• taste masking;
• specialized compression or lyophilization equipment.

Blister packaging is generally more appropriate than a bottle for moisture-sensitive ODTs.

Liquid formulations

A liquid product could target pediatric or swallowing-constrained populations, but pediatric positioning is regulated and clinically sensitive. Loperamide use in children is restricted by age, product labeling, and medical guidance. A liquid format therefore carries greater safety and labeling risk than a standard adult tablet.

Liquid excipient selection would need to address:

• preservative effectiveness;
• viscosity;
• pH;
• sedimentation;
• microbial control;
• flavor and bitterness;
• dosing-device accuracy;
• sugar-free and alcohol-free positioning.

Softgels

Softgels provide a familiar Imodium-like presentation and can improve swallowability. They require a liquid or semisolid fill, gelatin or alternative shell material, specialized encapsulation, and tighter stability controls.

The commercial benefit is a more branded consumer experience. The disadvantage is higher manufacturing cost and greater dependence on specialized suppliers.

What manufacturing and IP barriers affect loperamide products?

Manufacturing barriers are more important than active-ingredient patents. Key barriers include:

1. Content uniformity. The low dose increases blend and compression sensitivity.
2. Dissolution consistency. Lubricant level, compression force, and coating weight can alter release.
3. Packaging integrity. Unit-dose pouches and blisters require seal validation.
4. Raw-material qualification. Excipient variability can change flow and compression.
5. Contract-manufacturer capacity. Retail launches can fail if a supplier cannot support multiple pack counts.
6. Quality-system maturity. OTC products remain subject to cGMP, deviation control, complaint handling, and recall obligations.
7. Supply-chain resilience. A second-source strategy is valuable for loperamide API, film coating, packaging foil, and critical excipients.

A novel manufacturing process could support patent claims if it produces a demonstrable technical advantage, such as improved content uniformity, lower impurity formation, enhanced dissolution, or reduced solvent use. Routine substitution of one conventional excipient for another is unlikely to create strong patent protection without unexpected results.

What generic entry risks exist for GoodSense loperamide?

Generic entry risk is high because loperamide is mature, inexpensive, and widely supplied. The competitive threat comes from multiple channels rather than one patent challenger:

• pharmacy-counter generics;
• private-label retail brands;
• online sellers;
• contract-manufactured OTC products;
• value packs from mass merchants;
• imported or parallel-distributed products, subject to FDA compliance.

A new entrant can usually compete without overcoming a meaningful composition-of-matter patent. The main commercial barriers are retailer authorization, manufacturing scale, shelf placement, quality history, and price.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally associated with abbreviated new drug applications challenging listed patents for approved prescription products. It is not the central pathway for a standard OTC monograph loperamide product.

A Paragraph IV analysis becomes relevant only if the specific loperamide product is tied to an approved application with Orange Book-listed patents. For a conventional monograph-compliant GoodSense product, the relevant entry analysis is regulatory compliance and supply economics, not Paragraph IV litigation.

What is the patent litigation and settlement outlook?

The expected litigation risk for a standard GoodSense loperamide tablet is low. There is no apparent reason to expect high-value litigation over the basic active ingredient or routine immediate-release formulation.

Litigation risk would rise if a company launched:

• a patented abuse-deterrent loperamide formulation;
• a protected chewable or orally disintegrating system;
• a novel combination product;
• a patented manufacturing process;
• packaging that copies protected trade dress;
• a product marketed for a patented method of use.

Settlement agreements are therefore more likely to arise in a differentiated formulation or trademark dispute than in ordinary sale of a 2 mg generic tablet.

How does GoodSense compare with Imodium A-D?

Factor	GoodSense loperamide	Imodium A-D
Positioning	Value and private label	National brand
Active ingredient	Loperamide hydrochloride	Loperamide hydrochloride
Typical strength	2 mg	2 mg
Core dosage forms	Tablet, caplet, or capsule depending on SKU	Caplet, capsule, liquid, and other branded formats
Patent dependence	Low	Low for the legacy active ingredient; higher potential for branded formats
Price	Usually lower	Usually higher
Retail leverage	Retailer-specific	Broad national distribution
Consumer trust	Depends on retailer and packaging	Strong brand recognition
Differentiation	Pack count, price, format	Brand, convenience, formulation variety
Main risk	Commoditization	Substitution by private label

GoodSense is best positioned as a cost-efficient substitute. It is less likely to win through technical superiority unless it introduces a differentiated format, improved packaging, or a specific consumer-use advantage.

What licensing deals could create commercial value?

Licensing opportunities are limited for an ordinary loperamide tablet because the active ingredient and basic dosage form are widely available. More attractive opportunities include:

• licensing a taste-masking platform for chewables;
• acquiring a fast-disintegrating tablet technology;
• licensing child-resistant unit-dose packaging;
• partnering with a specialty manufacturer for softgels;
• licensing an abuse-deterrent platform;
• securing retailer-exclusive packaging or pack configurations;
• acquiring a second-source manufacturing arrangement.

A licensing deal should be evaluated against incremental retail value, not only formulation novelty. If the technology does not support a higher price, stronger shelf placement, lower returns, or lower manufacturing cost, its patent value may be limited.

What revenue exposure does loperamide create?

Loperamide is generally a low-price, high-volume OTC product. Revenue exposure is concentrated in:

• retail distribution agreements;
• seasonal gastrointestinal illness demand;
• travel-related purchases;
• emergency and convenience purchases;
• e-commerce replenishment;
• retailer private-label penetration.

The active ingredient itself does not support premium pricing. Margin depends on API cost, tablet yield, packaging format, freight, retailer margin, promotional allowances, and product returns.

The strongest commercial levers are:

1. larger pack sizes for household use;
2. small travel packs;
3. unit-dose blisters;
4. low-cost bottles for mass retail;
5. chewable or fast-dissolving formats;
6. lactose-free or gelatin-free positioning;
7. retailer-exclusive configurations.

Key Takeaways

• GoodSense loperamide hydrochloride is a mature OTC product with limited active-ingredient patent risk.
• The standard 2 mg tablet or capsule is highly exposed to generic and private-label competition.
• Excipient strategy should prioritize content uniformity, rapid disintegration, manufacturability, stability, and low cost.
• Chewables, orally disintegrating tablets, softgels, and improved unit-dose packaging offer stronger commercial differentiation.
• Method-of-use patents and Paragraph IV litigation are unlikely to drive risk for a conventional OTC monograph product.
• Manufacturing capability, retailer access, packaging economics, and quality compliance are more important than legacy loperamide patents.
• Abuse and cardiac-safety concerns make dosing controls, labeling discipline, and packaging strategy commercially important.[1]
• The strongest IP opportunities concern novel delivery systems, taste masking, packaging, and manufacturing processes rather than loperamide itself.

FAQs About GoodSense Loperamide Excipient and Commercial Strategy

Can GoodSense loperamide be reformulated without changing its regulatory pathway?

A formulation change may remain within the OTC pathway if the product continues to satisfy applicable monograph conditions and labeling requirements. A novel dosage form, new indication, or material change in active delivery may require a different regulatory assessment.

Is lactose-free loperamide commercially valuable?

Yes. A lactose-free formulation can remove a consumer concern and simplify retailer positioning. Its value is greatest when combined with sugar-free, gelatin-free, or clean-label claims supported by the complete formulation record.

Can an excipient combination be patented for loperamide?

Potentially, but routine substitution is weak patent material. A stronger claim would require a defined composition linked to unexpected dissolution, taste masking, stability, content uniformity, or abuse-deterrence results.

Is an loperamide liquid suitable for children?

A liquid format creates pediatric-use and dosing risks. Age restrictions, labeling, dose-device accuracy, and safety evidence must be evaluated before positioning the product for pediatric consumers.

What is the best commercial format for a new GoodSense competitor?

The lowest-risk entry is a conventional 2 mg immediate-release tablet or capsule in a low-cost bottle or blister. The higher-margin opportunity is a differentiated chewable, orally disintegrating product, or convenient unit-dose package with validated consumer benefits.

References

1. U.S. Food and Drug Administration. (2018). FDA warns about serious heart problems with high doses of the anti-diarrheal medicine loperamide (Imodium), including abuse and misuse. https://www.fda.gov
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 335: Antidiarrheal products for over-the-counter human use. https://www.ecfr.gov
3. U.S. Food and Drug Administration. (2020). Over-the-counter monograph reform under the Coronavirus Aid, Relief, and Economic Security Act. https://www.fda.gov
4. National Library of Medicine. (n.d.). DailyMed: Loperamide hydrochloride oral products. https://dailymed.nlm.nih.gov
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov velopment.